InflaRx News

InflaRx N.V. Announces Share Capital Amendment

TipRanksApr 25 17:31 ET

InflaRx N.V. Announces 2024 AGM Details

TipRanksApr 4 16:58 ET

Investor Optimism for InflaRx's INF904: Assessing Potential in CSU and HS Markets

TipRanksMar 24 21:25 ET

LifeSci Capital Reaffirms Their Hold Rating on InflaRx (IFRX)

TipRanksMar 22 15:05 ET

Express News | HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

Moomoo 24/7Mar 22 08:22 ET

Buy Rating Justified for InflaRx Despite Earnings Miss: Financial Stability and INF904's Market Potential

TipRanksMar 22 06:16 ET

InflaRx Advances Anti-Inflammatory Therapeutics

TipRanksMar 21 21:27 ET

InflaRx N.V. Targets Immuno-Dermatology Growth

TipRanksMar 21 07:57 ET

Express News | InflaRx's INF904 Will Initially Target Chronic Spontaneous Urticaria And Hidradenitis Suppurativa, With Initiation Of A Phase 2a PK Dose-ranging Study Expected By The End Of 2024, With Data Availability Anticipated In 2025

Moomoo 24/7Mar 21 07:15 ET

Express News | InflaRx Will Focus Development Activities And Resources Initially On Selected Indications In Immuno-dermatology, With Registrational-phase Vilobelimab And INF904

Moomoo 24/7Mar 21 07:14 ET

Express News | InflaRx FY EPS €(0.78) Down From €(0.67) YoY, Sales €63.09K

Moomoo 24/7Mar 21 07:13 ET

InflaRx Reports FY Results

Seeking AlphaMar 21 07:09 ET

InflaRx 2023 Loss/Shr EUR0.78 >IFRX

InflaRx 2023 Loss/Shr EUR0.78 >IFRX

Dow JonesMar 21 07:07 ET

Earnings Scheduled For March 21, 2024

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. • InflaRx (NASDAQ:IFRX) is projected to

BenzingaMar 21 06:15 ET

Earnings Preview: InflaRx

InflaRx (NASDAQ:IFRX) is set to give its latest quarterly earnings report on Thursday, 2024-03-21. Here's what investors need to know before the announcement.Analysts estimate that InflaRx will report

BenzingaMar 20 13:01 ET

InflaRx Hires New VP and Head of Investor Relations

InvestingFeb 22 07:46 ET

InflaRx Is Maintained at Buy by HC Wainwright & Co.

InflaRx Is Maintained at Buy by HC Wainwright & Co.

Dow JonesJan 25 11:33 ET

Buy Recommendation for InflaRx Amidst Strategic Initiatives and Promising Clinical Advances

TipRanksJan 25 11:25 ET

HC Wainwright & Co. Maintains Buy on InflaRx, Lowers Price Target to $8

HC Wainwright & Co. analyst Edward White maintains InflaRx with a Buy and lowers the price target from $9 to $8.

Analyst UpgradesJan 25 11:24 ET

Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), InflaRx (IFRX) and Eli Lilly & Co (LLY)

TipRanksJan 9 01:30 ET